Efficacy and safety analysis of cefoperazone sodium/sulbactam sodium combined with ulinastatin in the treatment of renal transplant recipients with severe pneumonia
Tong Qiang
Ju Siwei
Zeng Xi
Yuan Yuan
Abstract：Objective To evaluate the efficacy and safety of cefoperazone sodium/sulbactam sodium(CPZ-SBT)combined with ulinastatin in the treatment of renal transplant recipients with severe pneumonia(RTSP).Methods A retrospective analysis was performed on the clinical data of 74 RTSP patients admitted to General Hospital of Northern Theater Command of the Chinese People's Liberation Army from January 2022 to May 2025.The patients were divided into control group(treated with CPZ-SBT)and combination group(treated with CPZ-SBT combined with ulinastatin)according to the treatment regimen,with 37 cases in each group.Both groups received continuous treatment for more than 7 d.The clinical efficacy,clinical indicators,respiratory function indicators,inflammatory factor levels before and after treatment,and adverse reactions during treatment were recor-ded and compared between the two groups.Results Both groups were sensitive to CPZ-SBT treatment.The total effective rate of the combination group was slightly higher than that of the control group[97.3％(36/37)vs 89.2％(33/37)],but the difference was not statistically significant(P=0.165).The time to body temperature recovery,wheezing resolution,and cough resolution in the combination group were significantly shorter than those in the control group(all P＜0.05).After treatment,the arterial oxygen saturation and arterial partial pressure of oxygen in both groups were significantly higher than those before treatment,with the combination group showing higher values than the control group.The arterial partial pressure of carbon dioxide,procalcitonin,and C-reactive protein levels in both groups were significantly lower than those before treatment,and the combination group had lower levels than the control group(all P＜0.05).The total incidence of adverse reactions in the combination group was slightly higher than that in the control group[10.8％(4/37)vs 5.4％(2/37)],but the difference was not statistically significant(P=0.394).Conclusion CPZ-SBT combined with ulinastatin in the treatment of RTSP patients can effectively promote symptom recovery,improve respiratory function,and regulate inflammatory factor levels,with mild adverse reactions,showing good safety and efficacy.
Keywords：Renal transplantationSevere pneumoniaCefoperazone sodium/sulbactam sodiumUlinastatinEfficacySafety
Publication Date：2026-01-18
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：5( 22-26 )